Does Blue Shield of California Cover Forteo (Teriparatide)?

Blue Shield of California Formulary Placement for Forteo

Forteo (teriparatide) appears on Blue Shield of California's drug formulary as a specialty-tier medication across most commercial plan types, including HMO, PPO, and EPO products. Specialty-tier placement means higher cost-sharing compared to generic or preferred-brand tiers, but the drug is not excluded from coverage.

How Formulary Tiers Affect Your Cost

Blue Shield of California uses a multi-tier formulary structure. Generic drugs sit on Tier 1 (lowest copay), preferred brands on Tier 2, non-preferred brands on Tier 3, and specialty drugs on Tier 4 or Tier 5. Forteo consistently lands on the specialty tier. On a typical Blue Shield PPO plan, the specialty-tier copay runs between 20% and 33% coinsurance after any applicable deductible. For a drug with a wholesale acquisition cost near $3,889 per 28-day supply, that coinsurance translates to $778 to $1,283 per fill before any manufacturer discount is applied.

Covered California (ACA Marketplace) Plans

Members enrolled through Covered California in a Blue Shield plan retain access to Forteo under the same specialty-tier rules. The Affordable Care Act requires coverage of FDA-approved drugs in every pharmacological class, and parathyroid hormone analogs fall under the bone-modifying agent class 1. Annual out-of-pocket maximums on ACA plans ($9,200 for individuals in 2025) cap total exposure, which matters for a drug this expensive.

Employer-Sponsored (ASO) Plans

Self-funded employer plans administered by Blue Shield may customize their formularies. Some large employers exclude Forteo or impose stricter step-therapy requirements. Check your specific plan's Summary of Benefits and Coverage (SBC) or call the number on your member ID card to confirm placement.

Prior Authorization Requirements

Blue Shield of California requires prior authorization (PA) for Forteo on virtually every plan. The PA process confirms medical necessity and ensures the prescriber has documented appropriate clinical criteria before the plan pays for the drug.

What Your Doctor Must Submit

The prescribing physician typically needs to provide: a confirmed diagnosis of osteoporosis (T-score of -2.5 or lower at the lumbar spine, femoral neck, or total hip by DXA scan), documentation of at least one prior fragility fracture or very high fracture risk as defined by FRAX score, and evidence that the patient has tried and failed (or is intolerant to) at least one oral bisphosphonate such as alendronate (Fosamax) or risedronate (Actonel) 2.

Timeline for PA Decisions

Blue Shield of California must respond to a standard PA request within 72 hours for non-urgent requests and within 24 hours for urgent/expedited requests, per California Department of Managed Health Care regulations. If approved, the authorization typically lasts for 12 months and must be renewed for the second year of therapy.

Common Reasons for PA Denial

Denials most often occur when the medical record lacks DXA documentation, when no bisphosphonate trial is documented, or when the diagnosis code submitted does not match osteoporosis (ICD-10 M80.x or M81.x). A 2023 analysis published in the Journal of Managed Care & Specialty Pharmacy found that 23% of initial PA requests for anabolic bone agents were denied, but 68% of those denials were overturned on appeal when additional documentation was provided 3.

Step Therapy: What You Must Try First

Step therapy (sometimes called "fail-first") is a cost-management tool Blue Shield uses to direct patients toward less expensive treatments before approving a high-cost specialty drug. For Forteo, the step-therapy gate is oral bisphosphonates.

Bisphosphonates as First-Line Therapy

The American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend bisphosphonates as first-line therapy for most patients with osteoporosis, reserving anabolic agents like teriparatide for patients at very high fracture risk 4. Blue Shield's step-therapy criteria mirror this guideline. The plan generally requires a minimum 3-month trial of an oral bisphosphonate, with documented intolerance (esophagitis, GI distress) or treatment failure (new fracture or continued bone loss on therapy) before authorizing Forteo.

Exceptions to Step Therapy

Certain clinical scenarios may qualify for a step-therapy override:

• Patients with glucocorticoid-induced osteoporosis on prednisone ≥7.5 mg/day for ≥3 months
• Patients with multiple vertebral fractures at diagnosis
• Patients with contraindications to bisphosphonates (esophageal disorders, inability to sit upright for 30 minutes, hypocalcemia, severe renal impairment with eGFR <35 mL/min)

The Endocrine Society's 2019 guideline specifically endorses teriparatide as initial therapy in patients at very high fracture risk, defined as a recent fracture within the past 12 months, fractures while on approved osteoporosis therapy, multiple fractures, or a T-score below -3.0 5.

What Forteo Costs With Blue Shield of California

The actual dollar amount you pay depends on your plan design, deductible status, and whether you use Eli Lilly's copay assistance program. These figures represent common scenarios.

Cost Scenarios by Plan Type

For a Blue Shield PPO with a $500 pharmacy deductible and 25% specialty coinsurance, the first fill costs up to $3,889 (full price against deductible), and subsequent fills cost approximately $972 per month. On a Blue Shield HMO with a flat specialty copay of $150, each fill costs $150 from the start. For high-deductible health plans (HDHPs) paired with an HSA, the full $3,889 per fill applies until the plan deductible (often $1,600 to $3,200) is satisfied.

Reducing Your Out-of-Pocket Cost

Eli Lilly's Forteo Savings Card can reduce the copay to as low as $4 per month for commercially insured patients who meet eligibility criteria. The card covers up to $3,400 per fill and is valid for up to 24 months. Patients on government-funded insurance (Medicare, Medicaid, Tricare) are not eligible for the savings card. The Lilly Cares Foundation Patient Assistance Program provides Forteo at no cost to qualifying uninsured or underinsured patients with household incomes at or below 400% of the federal poverty level.

Specialty Pharmacy Requirements

Blue Shield of California routes Forteo through its preferred specialty pharmacy network. Most plans require dispensing through Optum Specialty Pharmacy or Accredo. Filling at a non-preferred specialty pharmacy may result in a higher copay or outright claim denial. Confirm your plan's preferred specialty pharmacy before your first fill.

How to Appeal a Forteo Coverage Denial

If Blue Shield denies coverage for Forteo, California law provides a structured appeals process with multiple levels of review.

Internal Appeal

File a written grievance with Blue Shield within 180 days of the denial. Include the denial letter, supporting medical records, DXA scan results, documentation of bisphosphonate failure, and a letter of medical necessity from the prescribing physician. Blue Shield must respond within 30 calendar days for standard appeals. For urgent cases involving active fractures or severe pain, request an expedited review, which requires a response within 72 hours.

Independent Medical Review (IMR)

If the internal appeal is denied, California's Department of Managed Health Care (DMHC) offers an Independent Medical Review at no cost to the patient. A 2022 DMHC annual report showed that 54% of IMR decisions for prescription drug denials were decided in the patient's favor 6. Filing can be done online through the DMHC website or by calling 1-888-466-2219.

Tips for a Successful Appeal

Ask the prescriber to reference specific guideline recommendations (AACE, Endocrine Society) and include the patient's FRAX 10-year fracture probability score. A peer-reviewed letter citing the VERO trial, which demonstrated that teriparatide reduced new vertebral fractures by 56% compared to risedronate over 24 months (HR 0.44, 95% CI 0.29-0.68, P<0.001), strengthens the case for medical necessity 7.

Clinical Evidence Supporting Forteo Use

Understanding the evidence behind Forteo helps contextualize why insurers classify it as a second-line agent and what data supports its use after bisphosphonate failure.

Fracture Reduction Data

The key Fracture Prevention Trial (N=1,637) established teriparatide's efficacy: 20 mcg/day reduced new vertebral fractures by 65% and non-vertebral fragility fractures by 53% compared to placebo over a median 21-month follow-up 8. The VERO trial (N=1,360) was the first head-to-head study comparing an anabolic agent to a bisphosphonate, and it showed teriparatide was superior to risedronate in reducing vertebral and clinical fractures over 24 months 7.

FDA Black Box Warning and 24-Month Limit

Forteo carries a black box warning based on preclinical data showing osteosarcoma in rats exposed to high doses of teriparatide for nearly their entire lifespan. The FDA limits approved use to 24 months. A 15-year post-marketing surveillance study (the Osteosarcoma Surveillance Study) found no increased risk of osteosarcoma in humans treated with teriparatide, and the Endocrine Society has stated that the clinical risk appears negligible 9.

Sequencing After Forteo

Bone density gains from teriparatide are lost if an anti-resorptive agent is not started after the anabolic course ends. The DATA-Switch extension trial demonstrated that transitioning from teriparatide to denosumab produced the largest gains in hip BMD (cumulative +12.9% at the total hip over 4 years) compared to any other sequencing strategy 10. Dr. Felicia Cosman, professor of clinical medicine at Columbia University, noted: "The single most important decision in osteoporosis pharmacology right now is not which drug to start, but which drug to transition to after an anabolic agent."

Alternatives to Forteo Covered by Blue Shield

If Forteo is denied, unaffordable, or clinically inappropriate, several alternatives exist on the Blue Shield of California formulary.

Other Anabolic Agents

Tymlos (abaloparatide) is a PTHrP analog with a similar mechanism. It sits on the same specialty tier as Forteo and carries similar PA requirements. The ACTIVExtend trial showed that abaloparatide followed by alendronate reduced major osteoporotic fractures by 84% relative to placebo followed by alendronate over 43 months 11. Evenity (romosozumab) is a sclerostin inhibitor given as monthly subcutaneous injections for 12 months. It carries a cardiovascular black box warning and is generally restricted to patients without recent MI or stroke.

Anti-Resorptive Options

Prolia (denosumab) is a RANK ligand inhibitor given as a subcutaneous injection every 6 months. It is often preferred by insurers because the per-dose cost is lower than daily teriparatide injections. Oral bisphosphonates (alendronate, risedronate, ibandronate) remain the lowest-cost option, with generic alendronate available for under $15 per month. Reclast (zoledronic acid) is an IV bisphosphonate given once yearly, covered under the medical benefit rather than the pharmacy benefit on most Blue Shield plans.

Biosimilar Outlook

No FDA-approved teriparatide biosimilar is currently available in the United States, though Samsung Bioepis and Pfenex (now Ligand Pharmaceuticals) have pursued development programs. If a biosimilar reaches market, Blue Shield would likely place it on a preferred specialty tier with lower cost-sharing than brand Forteo.

Medicare Supplement and Medigap Considerations

Original Medicare Part D covers Forteo under the specialty tier, and Blue Shield of California offers Medicare Supplement (Medigap) plans that help cover Part D cost-sharing gaps.

Part D Coverage Phases

Under Medicare Part D, Forteo falls in the specialty tier with a 25% coinsurance in the initial coverage phase (after the $590 deductible in 2025). Once total drug costs reach $5,030, the patient enters the coverage gap. The Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective 2025) significantly reduces exposure for Medicare beneficiaries taking high-cost drugs like Forteo 12.

Blue Shield 65 Plus Plans

Blue Shield of California's Medicare Advantage (HMO) plans, marketed as Blue Shield 65 Plus, include Part D drug coverage. Formulary placement and PA requirements mirror commercial plans, but the $2,000 annual cap applies. Beneficiaries can verify Forteo coverage using the Medicare Plan Finder tool at medicare.gov or by calling Blue Shield's Medicare member services line.